Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Abiomed, Inc.
  6. Summary
    ABMD   US0036541003

ABIOMED, INC.

(ABMD)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/14/2022 01/18/2022 01/19/2022 01/20/2022 01/21/2022 Date
301.22(c) 292.38(c) 302.02(c) 302.75(c) 304.57(c) Last
356 831 427 228 509 948 429 917 836 701 Volume
-1.82% -2.93% +3.30% +0.24% +0.60% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 1 021 M - -
Net income 2022 125 M - -
Net cash position 2022 523 M - -
P/E ratio 2022 112x
Yield 2022 -
Sales 2023 1 172 M - -
Net income 2023 227 M - -
Net cash position 2023 740 M - -
P/E ratio 2023 61,9x
Yield 2023 -
Capitalization 13 857 M 13 857 M -
EV / Sales 2022 13,1x
EV / Sales 2023 11,2x
Nbr of Employees 1 725
Free-Float -
More Financials
Company
ABIOMED, Inc. is a provider of medical devices, which provides circulatory support and oxygenation. The Company develops, manufactures and markets its products, which are designed to improve blood flow and/or performing the pumping function of the heart. Its products are used in the cardiac catheterization lab (cath lab), by interventional cardiologists and in the heart surgery suite by cardiac surgeons for patients... 
More about the company
Ratings of Abiomed, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C-
More Ratings
All news about ABIOMED, INC.
01/14Abiomed Third Quarter Fiscal 2022 Earnings and Conference Call Notification
BU
01/12ABIOMED : Corporate Presentation
PU
01/12Early Feasibility Study Demonstrates Successful Use of Abiomed's preCARDIA Technology
BU
01/12Early Feasibility Study Demonstrates Successful Use of Abiomed’s preCARDIA Technol..
CI
01/10Abiomed Gets Regulatory Approvals in Three Countries
MT
01/10Regulators Approve Impella 5.5 With SmartAssist in Japan and Hong Kong; US FDA Grants I..
BU
01/10Abiomed, Inc. Announces Regulators Grants Approvals for Impella Surgical Products
CI
01/07Morgan Stanley Raises Price Target for Abiomed to $292 From $269, Maintains Underweight..
MT
01/04Sensera Completes Sale of MicroDevices Business
MT
01/04Abiomed, Inc. acquired all the assets and business from Sensera, Inc. for $7.5 million ..
CI
2021Abiomed to Present at the 40th Annual J.P. Morgan Healthcare Conference
BU
2021Abiomed, Inc. agreed to acquire all the assets and business from Sensera, Inc. for $7.5..
CI
2021INSIDER SELL : Abiomed
MT
2021Abiomed to Present at Upcoming Investor Conferences
BU
2021Two Large Studies Demonstrate Complete Revascularization with Impella Heart Pumps Impro..
BU
More news
News in other languages on ABIOMED, INC.
01/13Erfolgreiche Anwendung der preCARDIA-Technologie von Abiomed in früher Machbarkeitsstud..
01/12Une première étude de faisabilité de la technologie preCARDIA d'Abiomed donne des résul..
01/12Une étude de faisabilité précoce démontre l'utilisation réussie de la technologie preCA..
01/11Aufsichtsbehörden genehmigen Impella 5.5 mit SmartAssist Herzpumpe in Japan und Hongkon..
01/10Les instances réglementaires autorisent la pompe Impella 5.5 avec SmartAssist au Japon ..
More news
Analyst Recommendations on ABIOMED, INC.
More recommendations
Chart ABIOMED, INC.
Duration : Period :
Abiomed, Inc. Technical Analysis Chart | ABMD | US0036541003 | MarketScreener
Technical analysis trends ABIOMED, INC.
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 9
Last Close Price 304,57 $
Average target price 378,40 $
Spread / Average Target 24,2%
EPS Revisions
Managers and Directors
Michael R. Minogue Chairman, President & Chief Executive Officer
Todd A. Trapp Chief Financial Officer & Vice President
Thorsten Sie▀ Chief Technology Officer & Vice President
Charles A. Simonton Chief Medical Officer
Laxmi N. Peri Vice President-Engineering
Sector and Competitors
1st jan.Capi. (M$)
ABIOMED, INC.-15.20%13 857
THERMO FISHER SCIENTIFIC-13.03%228 678
DANAHER CORPORATION-14.76%200 403
INTUITIVE SURGICAL, INC.-24.98%96 286
SIEMENS HEALTHINEERS AG-7.72%77 272
EDWARDS LIFESCIENCES CORPORATION-13.05%70 331